- RxPx, with support from DIGITAL, introduces the ‘AI Clinical Buddy System’ to revolutionize clinical trials.
- Aimed at enhancing patient recruitment, adherence, diversity, and engagement through advanced AI techniques.
- Collaboration involves industry leaders and academic partners to drive innovation in healthcare.
- DIGITAL’s investment signifies a commitment to advancing applied AI technologies in Canada.
- Consortium partners represent a diverse range of expertise, reinforcing global collaboration in healthcare innovation.
Main AI News:
The global landscape is witnessing a staggering increase in the prevalence of multiple chronic diseases, with one in three individuals affected. Despite this, a significant challenge persists in clinical trials, where a staggering 85% struggle to enroll a sufficiently diverse patient pool necessary for bringing crucial drugs to market. Recognizing this critical gap, RxPx, in collaboration with industry leaders and co-investment from DIGITAL, Canada’s Global Innovation Cluster for digital technologies, introduces the groundbreaking ‘AI Clinical Buddy System.’
This visionary initiative aims to harness the power of artificial intelligence to revolutionize patient recruitment, adherence, diversity, and engagement within clinical trials. Leveraging advanced machine learning techniques alongside persuasive, generative, and predictive AI approaches, the AI Clinical Buddy System is poised to streamline operational processes, enhance patient monitoring, and elevate levels of adherence, retention, and overall engagement.
“The essence of any clinical trial lies in expediting the delivery of life-saving treatments to the market, ensuring broad accessibility to those in need. The AI Clinical Buddy System stands as a beacon of hope, poised to benefit both life sciences companies and patient communities on a global scale. Our commitment to patient-centric AI over the past five years has culminated in this transformative project, and we are thrilled to collaborate with esteemed industry leaders,” affirms Lynda Brown-Ganzert, CEO of RxPx.
DIGITAL’s involvement underscores its dedication to advancing applied AI technologies. Nadia Shaikh-Naeem, Vice President of Programs at DIGITAL, expresses enthusiasm for this partnership, emphasizing its alignment with DIGITAL’s mission to bolster the efficacy and inclusivity of clinical trials. This initiative builds upon Canada’s burgeoning reputation in AI and reinforces international pathways for Canadian enterprises.
This pivotal project, supported by DIGITAL’s Technology Commercialization stream within the Horizon AI program, represents a concerted effort to harness Canada’s economic potential in applied AI. The consortium, comprising industry stalwarts such as Axial Bridge, uMed, OPTT Health, Aparito, along with esteemed academic partners including Dr. Martin-Ginis from UBC and Dr. Nayebi and Dr. Toshner from York University’s Heart and Lung Research Institute NIHR Clinical Research Facility, underscores a collaborative commitment to driving innovation and addressing critical healthcare challenges on a global scale.
Conclusion:
The introduction of the ‘AI Clinical Buddy System’ marks a significant leap forward in the evolution of clinical trials. By leveraging AI technologies, stakeholders can anticipate improved patient engagement, streamlined processes, and enhanced diversity in trial participants. This initiative not only underscores Canada’s prowess in applied AI but also signals a broader shift towards innovative approaches to address healthcare challenges. As such, the market can expect to witness accelerated advancements in patient-centric solutions and increased collaboration between industry and academia.
